Intended for healthcare professionals


EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

BMJ 2024; 385 doi: (Published 04 May 2024) Cite this as: BMJ 2024;385:q1025

This notice alerts readers to an error with this paper by Athina-Marina Metaxa and Mike Clarke (BMJ 2024;385:e078084. doi:10.1136/bmj-2023-078084, published 01 May 2024). The journal and the authors are investigating the problem. The study analysed data from randomised trials of psilocybin for the treatment of depression in adults. A methodological concern has been raised about an error in the calculation of standardised mean differences. This is likely to have overestimated the benefits of psilocybin. The authors are reviewing and responding to the error and its implications for the findings and conclusions of the paper. The authors’ response will be reviewed by The BMJ who will decide what further action is needed.